Six leading cancer centers have joined forces to form Cancer Core Europe—a European cancer association carrying out innovative research propelling cancer medicine into a new era.

Cancer Core Europe builds upon the efforts of previous larger European consortia such as the EurocanPlatform, a project bringing together 28 European cancer institutions and organizations that was funded by the European Commission under the seventh framework program. Cancer Core Europe’s members are driven by a strong will to reshape the cancer research model to ultimately increase the European Union’s competitiveness as a place to conduct cutting-edge research that’s translated to the clinic to deliver more personalized medicine.

Cancer Core Europe’s efforts look to pave the way for a multi-site cancer institute that will drive the development of new treatments and earlier diagnoses for patients and more effective cancer prevention for Europe’s citizens.

In recent years, both new treatments targeting specific molecular alterations within tumors and immunotherapy have shown remarkable successes; however many challenges remain. More than half of all treated cancer patients live five years or longer, but work still remains to improve these figures. Cancer Core Europe brings together the expertise and critical mass required to effectively move translational research into the clinic, bringing breakthrough discoveries to benefit patients at an appropriate cost. Providing an environment where basic, translational, and clinical research occur side-by-side in our centers means that patients can benefit directly from experimental findings. Likewise, observations made in the clinic inform research being carried out. Cancer Core Europe, with the support of patient advocates, embraces this patient-centered approach. Sharing is essential—the complementary expertise of each center will sustain a common infrastructure providing patients with access to cutting-edge therapies, targeted for each patient and including immune therapies. Collective efforts to pool information from clinical, environmental, genomic, imaging and immune biology databases, will transform clinicians’ and researchers’ approach to cancer research, thereby permitting a deeper understanding than any single center could achieve on its own. Dissemination of findings to the public and specialists and training the future generation of oncologists will contribute to improving cancer health in Europe.

Going beyond borders to unite innovative centers of excellence is Cancer Core Europe’s vision: to effectively translate research progress to the clinic for the benefit of patients.

Task force working group aims

Cancer Core Europe will drive innovative translational research along several axes by taking an innovative approach to

  • sharing genomic and biological marker data as well as clinical and imaging data, then developing predictive modeling by mining this shared data,
  • developing biomarkers (e.g. immune markers) and clinical imaging technologies to predict response to therapy,
  • running cutting-edge clinical trials across all six centers with harmonized procedures,
  • training the future generation of researchers and clinicians.


From the Cancer Core Europe Webpage.

Cancer Core Europe Position paper